CN113197313A - Probiotic composition with functions of improving insulin resistance and fasting blood glucose and preparation method thereof - Google Patents

Probiotic composition with functions of improving insulin resistance and fasting blood glucose and preparation method thereof Download PDF

Info

Publication number
CN113197313A
CN113197313A CN202010911082.0A CN202010911082A CN113197313A CN 113197313 A CN113197313 A CN 113197313A CN 202010911082 A CN202010911082 A CN 202010911082A CN 113197313 A CN113197313 A CN 113197313A
Authority
CN
China
Prior art keywords
parts
powder
probiotic composition
bifidobacterium lactis
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010911082.0A
Other languages
Chinese (zh)
Other versions
CN113197313B (en
Inventor
栾少萌
康小红
陈建国
滕国新
王凡
孙健
赵红峰
孙二娜
李周勇
韩雨婷
孟昭旭
李海楠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Mengniu Dairy Group Co Ltd
Original Assignee
Inner Mongolia Mengniu Dairy Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Mengniu Dairy Group Co Ltd filed Critical Inner Mongolia Mengniu Dairy Group Co Ltd
Priority to CN202010911082.0A priority Critical patent/CN113197313B/en
Publication of CN113197313A publication Critical patent/CN113197313A/en
Application granted granted Critical
Publication of CN113197313B publication Critical patent/CN113197313B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/015—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/513—Adolescentes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Abstract

The invention relates to the field of functional foods, in particular to a probiotic composition capable of improving insulin resistance and fasting blood glucose and a preparation method thereof, wherein the probiotic composition capable of improving insulin resistance and fasting blood glucose comprises the following components: bifidobacterium lactis (Bifidobacterium lactis) MN-Gup, Lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, Bifidobacterium lactis (Bifidobacterium lactis) B420, Bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 and Lactobacillus reuteri (Lactobacillus reuteri) SD 5865; the probiotics in the probiotic composition synergistically play a role in reducing the insulin resistance index and reducing the fasting blood glucose.

Description

Probiotic composition with functions of improving insulin resistance and fasting blood glucose and preparation method thereof
Technical Field
The invention relates to the field of functional foods, in particular to a probiotic composition capable of improving insulin resistance and fasting blood glucose and a preparation method thereof.
Background
Diabetes mellitus is a metabolic disease group characterized by the increase of chronic blood glucose (short for blood sugar), the prevalence rate of the diabetes mellitus is increased rapidly along with the improvement of living standard of people, the change of life style is increased rapidly, the diabetes mellitus becomes the third most non-infectious disease after cardiovascular diseases and tumors in developed countries, the diabetes mellitus can cause multi-system damage, the chronic progressive change of tissues such as eyes, kidneys, nerves, hearts and blood vessels is caused, functional defects and failure are caused, and the human health is seriously threatened. Diabetes is classified into type 1 diabetes, type 2diabetes, gestational diabetes and other types of diabetes according to the cause of the disease. Among them, Type 2diabetes (T2 DM) refers to a metabolic disorder characterized by hyperglycemia due to destruction of islet β cells by insulin resistance or relative insulin deficiency, and is one of the largest number of diabetes subtypes.
Defects in insulin resistance and islet beta cell secretion are important pathophysiological changes in the pathogenesis of T2 DM. Impaired Fasting Glucose (IFG) belongs to an intermediate state between normal glucose metabolism and diabetes, known as pre-diabetes. Any diabetic may undergo an IFG phase during the onset of the disease. Therefore, improvement of insulin resistance and fasting plasma glucose is very important for relieving diabetes, especially T2 DM. Therefore, the invention provides a probiotic composition capable of improving insulin resistance and fasting blood glucose and a preparation method thereof.
Disclosure of Invention
Therefore, the technical problem to be solved by the present invention is to provide a probiotic composition with effects of improving insulin resistance and fasting blood glucose and a preparation method thereof.
Therefore, the invention provides the following technical scheme:
a probiotic composition having improved insulin resistance and fasting plasma glucose comprising: bifidobacterium lactis (Bifidobacterium lactis) MN-Gup, Lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, Bifidobacterium lactis (Bifidobacterium lactis) B420, Bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 and Lactobacillus reuteri (Lactobacillus reuteri) SD 5865.
Further, the weight portions are as follows:
1-50 parts of bifidobacterium lactis MN-Gup powder;
1-50 parts of lactobacillus acidophilus NCFM powder;
0.1-20 parts of bifidobacterium lactis B420 powder;
1-50 parts of bifidobacterium adolescentis BA02 bacterial powder; and
0.1-30 parts of lactobacillus reuteri SD5865 powder.
Further, the food comprises food raw materials and/or food or medically acceptable auxiliary materials or additives.
Further, the food raw material is selected from at least one of stachyose, inulin, fructo-oligosaccharide, pumpkin powder and resistant dextrin, and is used for enhancing the proliferation and efficacy effects of the probiotics.
Further, the adjuvant or additive includes silicon dioxide for improving the fluidity of the formulation.
Further, the probiotic composition also comprises the following components in parts by weight:
0-100 parts of stachyose;
0-80 parts of inulin;
0-80 parts of fructo-oligosaccharide;
0-50 parts of pumpkin powder;
0-100 parts of resistant dextrin;
0-10 parts of silicon dioxide.
Further, the probiotic composition comprises the following components in parts by weight:
1-5 parts of bifidobacterium lactis MN-Gup powder;
1-5 parts of lactobacillus acidophilus NCFM powder;
0.5-2 parts of bifidobacterium lactis B420 powder;
1-5 parts of bifidobacterium adolescentis BA02 bacterial powder;
1-3 parts of lactobacillus reuteri SD5865 powder;
30-60 parts of stachyose;
30-60 parts of inulin;
10-30 parts of fructo-oligosaccharide;
10-20 parts of pumpkin powder;
30-80 parts of resistant dextrin; and
0.2-1 part of silicon dioxide.
A preparation method of a probiotic composition for improving insulin resistance and fasting blood glucose comprises the steps of weighing selected components according to selected parts by weight, and then uniformly mixing.
Further, in the preparation method, the selected food raw materials and/or auxiliary materials or additives are weighed according to the selected weight parts and are uniformly mixed;
weighing and uniformly mixing the bacterial powder according to the selected weight part to obtain a bacterial powder mixture;
and (3) uniformly mixing the mixture of the food raw materials and/or the auxiliary materials or the additives with the mixture of the fungus powder.
Further, in the preparation method, inulin and pumpkin powder are weighed and uniformly mixed to be marked as material A;
respectively weighing stachyose, fructo-oligosaccharide, part of resistant dextrin and silicon dioxide for later use;
weighing stachyose and part of resistant dextrin, mixing uniformly to obtain material B;
respectively weighing fructo-oligosaccharide and silicon dioxide for later use;
weighing the rest part of resistant dextrin, and powders of Bifidobacterium lactis MN-Gup, Lactobacillus acidophilus NCFM, Bifidobacterium lactis B420, Bifidobacterium adolescentis BA02 and Lactobacillus reuteri SD5865, mixing well, and marking as material C;
uniformly mixing the material A, the material B, the material C, the fructo-oligosaccharide and the silicon dioxide.
The technical scheme of the invention has the following advantages:
1. the invention provides a probiotic composition for improving insulin resistance and fasting blood glucose, which comprises the following components: bifidobacterium lactis (Bifidobacterium lactis) MN-Gup, Lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, Bifidobacterium lactis (Bifidobacterium lactis) B420, Bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 and Lactobacillus reuteri (Lactobacillus reuteri) SD 5865; the applicant finds that in human clinical research, compared with normal population, the intestinal bifidobacteria of adult diabetes patients are significantly less, and particularly the bifidobacterium adolescentis is obviously reflected; the lactobacillus is increased, but the lactobacillus is not related to inflammation factors (C-reactive protein) causing diabetes, and may be related to the reduction of bifidobacteria to cause the occupation of lactobacillus, and inflammatory molecules can more easily enter cells at the stage, and a series of reactions are caused to block the information transmission of insulin in the cells to cause the abnormal action of the insulin, so that the body can generate insulin resistance.
2. The invention provides a probiotic composition for improving insulin resistance and fasting blood glucose, which comprises the following components: the weight portion of the material is as follows: 1-50 parts of bifidobacterium lactis MN-Gup powder; 1-50 parts of lactobacillus acidophilus NCFM powder; 0.1-20 parts of bifidobacterium lactis B420 powder; 1-50 parts of bifidobacterium adolescentis BA02 bacterial powder; and 0.1-30 parts of lactobacillus reuteri SD5865 powder; under the proportion, the bifidobacterium lactis MN-Gup, the lactobacillus acidophilus NCFM, the bifidobacterium lactis B420, the bifidobacterium adolescentis BA02 and the lactobacillus reuteri SD5865 have strong mutual synergistic action, and the effects of reducing the insulin resistance index and reducing the fasting blood glucose are more obvious.
3. The probiotic composition capable of improving insulin resistance and fasting blood glucose also comprises food raw materials, wherein the food raw materials are selected from at least one of stachyose, inulin, fructo-oligosaccharide, pumpkin powder and resistant dextrin, and the food raw materials can promote the proliferation of bifidobacterium lactis MN-Gup, lactobacillus acidophilus NCFM, bifidobacterium lactis B420, bifidobacterium adolescentis BA02 and lactobacillus reuteri SD5865 on one hand and have a certain auxiliary effect on blood glucose and insulin reactions on the other hand.
4. The invention provides a probiotic composition capable of improving insulin resistance and fasting blood glucose, which comprises the following components in parts by weight: 1-5 parts of bifidobacterium lactis MN-Gup powder; 1-5 parts of lactobacillus acidophilus NCFM powder; 0.5-2 parts of bifidobacterium lactis B420 powder; 1-5 parts of bifidobacterium adolescentis BA02 bacterial powder; 1-3 parts of lactobacillus reuteri SD5865 powder; 30-60 parts of stachyose; 30-60 parts of inulin; 10-30 parts of fructo-oligosaccharide; 10-20 parts of pumpkin powder; 30-80 parts of resistant dextrin; and silicon dioxide, 0.2-1 part; the composition has a proper proportion, can directly rely on the action of 5 probiotics in intestinal tracts, relieves inflammation in vivo, improves insulin sensitivity, and promotes blood glucose metabolism, thereby reducing fasting blood glucose and achieving the effect of assisting in reducing blood glucose.
5. According to the preparation method of the probiotic composition capable of improving insulin resistance and fasting blood glucose, due to the fact that the moisture content of the pumpkin powder is high, inulin with a high formula ratio and low moisture content is selected to be mixed with the pumpkin powder, and the inulin and the pumpkin powder are uniformly mixed and marked as the material A; mixing the other stachyose with higher water content with part of resistant dextrin, and uniformly mixing to obtain a material B; respectively weighing the rest fructo-oligosaccharide and silicon dioxide with lower water content for later use; because the weight of the bacteria powder is light, the rest resistant dextrin needs to be weighed and mixed with the bacteria powder of bifidobacterium lactis MN-Gup, lactobacillus acidophilus NCFM, bifidobacterium lactis B420, bifidobacterium adolescentis BA02 and lactobacillus reuteri SD5865, so that the mixing uniformity of the formula is improved, and the uniformly mixed premix is marked as material C; uniformly mixing the material A, the material B, the material C, the fructo-oligosaccharide and the silicon dioxide.
Detailed Description
The following examples are provided to further understand the present invention, not to limit the scope of the present invention, but to provide the best mode, not to limit the content and the protection scope of the present invention, and any product similar or similar to the present invention, which is obtained by combining the present invention with other prior art features, falls within the protection scope of the present invention.
The examples do not show the specific experimental steps or conditions, and can be performed according to the conventional experimental steps described in the literature in the field. The reagents or instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially.
The bifidobacterium lactis MN-Gup powder in the following examples is prepared according to a conventional method, and the method can be as follows:
freezing and storing seeds of bifidobacterium lactis MN-Gup in a freezing storage tube, activating and continuously activating for three generations in a culture medium of MRS + 0.05% L-cysteine hydrochloride at 37 ℃, inoculating a leavening agent into a fermentation tank containing the culture medium of MRS + 0.05% L-cysteine hydrochloride for fermentation, centrifuging by a disc centrifuge after the fermentation is finished, collecting thalli, mixing the thalli with a protective agent containing trehalose, emulsifying, freeze-drying in a freeze-dryer, and crushing to obtain bacterial powder, wherein the number of viable bacteria in the bacterial powder is more than or equal to 5000 hundred million CFU/g.
Lactobacillus acidophilus NCFM bacterial powder, bifidobacterium lactis B420 bacterial powder, bifidobacterium adolescentis BA02 bacterial powder, lactobacillus reuteri SD5865 bacterial powder, lactobacillus plantarum bacterial powder, food raw materials and auxiliary materials or additives are all commercially available products.
The Bifidobacterium animalis subsp.lactis Mn-Gup is preserved in the China general microbiological culture Collection center of the culture Collection of microorganisms with the preservation number of CGMCC No.15578 and the preservation date of 2018, 4 and 10. In the present invention, Bifidobacterium animalis subsp.lactis (Bifidobacterium animalis) MN-Gup, simply referred to as Bifidobacterium lactis MN-Gup, is used.
Lactobacillus acidophilus NCFM (viable count is more than or equal to 2000 hundred million CFU/g), bifidobacterium lactis B420 (viable count is more than or equal to 4000 hundred million CFU/g), bifidobacterium adolescentis BA02 (viable count is more than or equal to 1000 hundred million CFU/g) and lactobacillus reuteri SD5865 (viable count is more than or equal to 3500 hundred million CFU/g), wherein the strains are all purchased from Dupont danisc, Probiotical Italy and Probi Sweden. Lactobacillus plantarum bacterial powder (the number of viable bacteria is more than or equal to 1000 hundred million CFU/g).
Example 1
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formula is as follows in table 1:
TABLE 1 probiotic composition formula
Figure BDA0002663286810000081
Example 2
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formula is as follows in table 2:
TABLE 2 probiotic composition formula
Figure BDA0002663286810000082
Example 3
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formulation is shown in table 3 below:
TABLE 3 probiotic composition formula
Figure BDA0002663286810000083
Figure BDA0002663286810000091
Example 4
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formulation is shown in table 4 below:
TABLE 4 probiotic composition formula
Figure BDA0002663286810000092
Example 5
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formulation is as follows in table 5:
TABLE 5 probiotic composition formula
Figure BDA0002663286810000093
Example 6
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formulation is shown in table 6 below:
TABLE 6 probiotic composition formula
Figure BDA0002663286810000101
Example 7
The present embodiment provides a probiotic composition with improved insulin resistance and fasting blood glucose, and the formulation is as follows in table 7:
TABLE 7 probiotic composition formula
Figure BDA0002663286810000102
Example 8
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formulation is as follows in table 8:
TABLE 8 probiotic composition formula
Figure BDA0002663286810000103
Example 9
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formulation is as follows in table 9:
TABLE 9 probiotic composition formula
Figure BDA0002663286810000111
Example 10
The present embodiment provides a probiotic composition with effects of improving insulin resistance and fasting blood glucose, and the formulation is as follows in table 10:
TABLE 10 probiotic composition formula
Figure BDA0002663286810000112
Example 11
The present embodiment provides a probiotic composition with improved insulin resistance and fasting blood glucose, and the formulation is as follows in table 11:
TABLE 11 probiotic composition formula
Figure BDA0002663286810000113
Figure BDA0002663286810000121
Example 12
The present embodiment provides a probiotic composition with improved insulin resistance and fasting blood glucose, and the formulation is as follows in table 12:
TABLE 12 probiotic composition formula
Figure BDA0002663286810000122
Example 13
This example provides a method of preparing the probiotic composition of example 1 with improved insulin resistance and fasting plasma glucose, comprising the steps of:
(1) weighing inulin and pumpkin powder according to the formula amount, and uniformly mixing to obtain a material A;
(2) weighing stachyose according to the formula amount, mixing with part of resistant dextrin, and mixing uniformly to obtain material B for later use;
(3) weighing fructo-oligosaccharide and silicon dioxide according to the formula ratio for later use
(4) Weighing the rest part of the resistant dextrin and the formulated bifidobacterium lactis MN-Gup powder, lactobacillus acidophilus NCFM powder, bifidobacterium lactis B420 powder, bifidobacterium adolescentis BA02 powder and lactobacillus reuteri SD5865 powder, uniformly mixing and marking as material C;
(5) uniformly mixing the material A, the material B, the material C, the fructo-oligosaccharide and the silicon dioxide.
Example 14
Examples 2-5, and examples 8-12 probiotic compositions having improved insulin resistance and fasting plasma glucose were prepared in the same manner as in example 13.
Example 15
This example provides a method of preparing the probiotic composition of example 6 with improved insulin resistance and fasting plasma glucose, comprising the steps of: weighing and uniformly mixing bifidobacterium lactis MN-Gup powder, lactobacillus acidophilus NCFM powder, bifidobacterium lactis B420 powder, bifidobacterium adolescentis BA02 powder, lactobacillus reuteri SD5865 powder and resistant dextrin according to the formula ratio.
Example 16
This example provides the same preparation method of the probiotic composition with improved insulin resistance and fasting plasma glucose of example 7 as example 15.
Comparative example
The probiotic compositions of comparative examples 1-6, having improved insulin resistance and fasting plasma glucose, were formulated as follows:
TABLE 13 probiotic composition formula
Figure BDA0002663286810000131
TABLE 14 probiotic composition formula
Figure BDA0002663286810000132
Figure BDA0002663286810000141
The preparation methods of the probiotic compositions of comparative examples 1 to 6 having the effects of improving insulin resistance and fasting plasma glucose only differ from those of example 13 in that, in step (4), the remaining part of the resistant dextrin was weighed and mixed with formulated amounts of bifidobacterium lactis MN-Gup powder, lactobacillus acidophilus NCFM powder, bifidobacterium lactis B420 powder, bifidobacterium adolescentis BA02 powder, lactobacillus reuteri SD5865 powder and/or lactobacillus plantarum powder to be recorded as material C.
Experimental example 1
Firstly, experimental design:
the detection basis is as follows: national food and drug administration [ 2012 ] annex 3 auxiliary hypoglycemic function evaluation method;
test animals:
SPF SD rat 160 +/-20 g, male, animal after being bought and adapted to environment for 5 days, normal animal blood sugar reducing experiment.
High-heat energy feed: 10% of lard, 15% of sucrose, 15% of yolk powder, 5% of casein, 1.2% of cholesterol, 0.2% of sodium cholate, 0.6% of calcium bicarbonate, 0.4% of stone powder and 52.6% of mouse maintaining material.
A test article: the probiotic compositions of examples 1, 2, 6 and comparative examples 1-6, having the formulation shown in Table 14 below, were administered to rats at a dose of 10ml/kg BW (2.68 g of each of the test samples of example 2 and example 6 dissolved in 10ml of deionized water, 1.34g of each of the other test samples dissolved in 10ml of deionized water)
Table 14 test article formulations
Figure BDA0002663286810000151
Figure BDA0002663286810000161
Grouping experiments:
hyperglycemia model hypoglycemic experiment: setting an experimental group to be respectively given a test article, 1 blank control group and 1 model control group, giving deionized water to the model control group, and performing intragastric administration and continuous intragastric administration for 33d according to 10mL/kg & BW for the experimental group and the model control group.
II, an experimental method:
hyperglycemia model hypoglycemic experiments (alloxan induced insulin resistant glucose/lipid metabolism disorder model)
The molding method comprises the following steps: rats were acclimatized to normal maintenance feed for 5 days, fasted for 3-4h, tail blood was collected, and blood glucose level before glucose administration (i.e., 0h) was measured, and blood glucose level after 2.5 g/kg. BW glucose administration was 0.5h and 2h, respectively, as the animal basis value of the batch. Grouping at 0h, 0.5h blood glucose level, namely blank control group, model control group and experimental group, each group is 15. The blank control group was left untreated, the test group was dosed with test sample and the model control group was dosed with the same volume of deionized water for 33 consecutive days. The maintenance feed is fed to each group, the high-heat energy feed is replaced to the model control group and the experimental group after 1 week, after 3 weeks, the model control group and the experimental group are fasted for 24h (without water prohibition), alloxan 103-105mg/kg & BW is given for intraperitoneal injection, and the injection amount is 1ml/100g of body weight. After injection, high-heat-energy feed is continuously fed for 3-5 days. After the test is finished, the animals in each group are fasted for 3-4h, and fasting blood sugar, sugar tolerance, serum insulin, cholesterol and triglyceride levels are detected.
Test index-fasting blood glucose and glucose tolerance
Fasting for 3-4h, determining fasting blood glucose, namely blood glucose value before (0h) glucose administration, administering probiotic composition test samples with different formulas and dosages to experimental groups, administering deionized water with the same volume to model control group, not treating blank control group, orally administering glucose 2.5g/kg & BW to groups after 15-20 min, and determining blood glucose value of groups after 0.5h and 2 h.
Measurement of indicators-Cholesterol and triglyceride
And (3) fasting animals of each group for 3-4h, detecting serum cholesterol and triglyceride, if the serum cholesterol or triglyceride of the model control group is obviously increased, comparing with a blank control group, determining that the model lipid metabolism disorder is established, and observing the blood lipid change of the model control group and the test sample group on the basis.
Measurement of index-insulin
The animals in each group are fasted for 3-4h, serum insulin is detected, and the insulin resistance index of the model control group and the blank control group is not obviously reduced. And observing the insulin resistance of the model control group and the test sample group.
Figure BDA0002663286810000171
Evaluation indexes are as follows: one of the two indexes of fasting blood sugar and glucose tolerance is positive, the blood fat (total cholesterol and triglyceride) is not obviously increased, and the fasting blood sugar of normal animals is not influenced, so that the positive result of the animal experiment of the function of assisting blood sugar reduction of the tested sample can be judged. The efficacy of the composition after drying was further evaluated.
Third, experimental results
(1) Fasting blood sugar
Fasting blood glucose results are shown in table 15, and the example 2 group, which is 2 times the dose of the example 1 group, can significantly reduce fasting blood glucose, and is also significantly better than the example 1 group. Therefore, the probiotic composition of the example 2 has a certain auxiliary blood sugar reducing effect on the whole and is a better formula.
TABLE 15 fasting plasma glucose before and after the experiment of hyperglycemia model rat
Figure BDA0002663286810000181
P <0.05 compared to model control, P <0.01 compared to model control.
(2) Triglyceride (TG)
Results of Triglyceride (TG) as can be seen from table 16 below, the example 2 group, which is 2 times the dose of the example 1 group, is able to significantly reduce triglyceride levels, and is also significantly better than the example 1 group. Therefore, the probiotic composition of the example 2 group has a certain triglyceride reduction effect as a whole, and is a better formula.
TABLE 16 Effect of serum CHO, TG after experiment of hyperglycemia model rat (X + -SD)
Figure BDA0002663286810000182
Figure BDA0002663286810000191
P <0.05 compared to model control, P <0.01 compared to model control.
(3) Insulin resistance
The results of insulin resistance are shown in table 17 below, and the probiotic composition of the example 2 group is capable of significantly reducing the insulin resistance index, and is also significantly better than the probiotic composition of the example 1 group. Therefore, the probiotic composition of the group of example 2 has certain effects of improving insulin resistance, improving insulin sensitivity and contributing to improvement of blood sugar level, and is a better formula.
TABLE 17 post-experiment insulin levels and insulin resistance index in hyperglycemic model rats
Figure BDA0002663286810000192
Figure BDA0002663286810000201
P <0.05 compared to model control, P <0.01 compared to model control.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims (10)

1. A probiotic composition having the effects of improving insulin resistance and fasting plasma glucose, comprising: bifidobacterium lactis (Bifidobacterium lactis) MN-Gup, Lactobacillus acidophilus (Lactobacillus acidophilus) NCFM, Bifidobacterium lactis (Bifidobacterium lactis) B420, Bifidobacterium adolescentis (Bifidobacterium adolescentis) BA02 and Lactobacillus reuteri (Lactobacillus reuteri) SD 5865.
2. The probiotic composition according to claim 1, characterized in that it comprises: the weight portion of the material is as follows:
1-50 parts of bifidobacterium lactis MN-Gup powder;
1-50 parts of lactobacillus acidophilus NCFM powder;
0.1-20 parts of bifidobacterium lactis B420 powder;
1-50 parts of bifidobacterium adolescentis BA02 bacterial powder; and
0.1-30 parts of lactobacillus reuteri SD5865 powder.
3. The probiotic composition according to claim 1 or 2, characterized in that it further comprises food raw materials, and/or food or medically acceptable adjuvants or additives.
4. The probiotic composition according to claim 3, characterized in that the food material is selected from at least one of stachyose, inulin, fructo-oligosaccharide, pumpkin powder and resistant dextrin.
5. The probiotic composition according to claim 3, characterized in that the adjuvant or additive comprises silicon dioxide.
6. The probiotic composition according to claim 4 or 5, characterized by further comprising the following components in parts by weight:
0-100 parts of stachyose;
0-80 parts of inulin;
0-80 parts of fructo-oligosaccharide;
0-50 parts of pumpkin powder;
0-100 parts of resistant dextrin; and
0-10 parts of silicon dioxide.
7. The probiotic composition according to claim 6, characterized by comprising the following components in parts by weight:
1-5 parts of bifidobacterium lactis MN-Gup powder;
1-5 parts of lactobacillus acidophilus NCFM powder;
0.5-2 parts of bifidobacterium lactis B420 powder;
1-5 parts of bifidobacterium adolescentis BA02 bacterial powder;
1-3 parts of lactobacillus reuteri SD5865 powder;
30-60 parts of stachyose;
30-60 parts of inulin;
10-30 parts of fructo-oligosaccharide;
10-20 parts of pumpkin powder;
30-80 parts of resistant dextrin; and
0.2-1 part of silicon dioxide.
8. A preparation method of a probiotic composition capable of improving insulin resistance and fasting blood glucose is characterized by comprising the steps of weighing selected components in parts by weight and then uniformly mixing.
9. The method of claim 8, comprising:
weighing selected food raw materials and/or auxiliary materials or additives according to selected parts by weight, and uniformly mixing;
weighing and uniformly mixing the bacterial powder according to the selected weight part to obtain a bacterial powder mixture;
and (3) uniformly mixing the mixture of the food raw materials and/or the auxiliary materials or the additives with the mixture of the fungus powder.
10. The method of claim 8, comprising:
weighing inulin and pumpkin powder, and uniformly mixing to obtain a material A;
weighing stachyose and part of resistant dextrin, mixing uniformly to obtain material B;
respectively weighing fructo-oligosaccharide and silicon dioxide for later use;
weighing the rest part of the resistant dextrin, mixing with bifidobacterium lactis MN-Gup, lactobacillus acidophilus NCFM, bifidobacterium lactis B420, bifidobacterium adolescentis BA02 and lactobacillus reuteri SD5865 powder, and marking the uniformly mixed premix as material C;
uniformly mixing the material A, the material B, the material C, the fructo-oligosaccharide and the silicon dioxide.
CN202010911082.0A 2020-09-02 2020-09-02 Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof Active CN113197313B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010911082.0A CN113197313B (en) 2020-09-02 2020-09-02 Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010911082.0A CN113197313B (en) 2020-09-02 2020-09-02 Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof

Publications (2)

Publication Number Publication Date
CN113197313A true CN113197313A (en) 2021-08-03
CN113197313B CN113197313B (en) 2023-10-27

Family

ID=77025039

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010911082.0A Active CN113197313B (en) 2020-09-02 2020-09-02 Probiotic composition with effects of improving insulin resistance and fasting blood glucose and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113197313B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113197288A (en) * 2020-08-31 2021-08-03 内蒙古蒙牛乳业（集团）股份有限公司 Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof
CN115137757A (en) * 2022-07-29 2022-10-04 承葛健康科技(广东)有限公司 Probiotic composition assisting in reducing blood sugar

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107291A1 (en) * 2009-06-19 2012-05-03 Danisco A/S Bifidobacteria for treating diabetes and related conditions
CN106619743A (en) * 2016-12-28 2017-05-10 山东龙力生物科技股份有限公司 Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink
CN109481510A (en) * 2018-10-11 2019-03-19 张军毅 It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof
CN109998113A (en) * 2019-04-18 2019-07-12 广东省微生物研究所（广东省微生物分析检测中心） A kind of functional food of the probiotics preparation with effect of lowering blood sugar
CN110354148A (en) * 2019-08-19 2019-10-22 江南大学 Bifidobacterium adolescentis CCFM1061 is preparing the application in functional microbial inoculum, food and/or drug
CN111346114A (en) * 2018-12-21 2020-06-30 深圳市华大农业应用研究院 Application of lactobacillus reuteri

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107291A1 (en) * 2009-06-19 2012-05-03 Danisco A/S Bifidobacteria for treating diabetes and related conditions
CN102458415A (en) * 2009-06-19 2012-05-16 丹尼斯科公司 Bifidobacteria for treating diabetes and related conditions
CN104770739A (en) * 2009-06-19 2015-07-15 杜邦营养生物科学有限公司 Bifidobacteria for treating diabetes and related conditions
CN104784694A (en) * 2009-06-19 2015-07-22 杜邦营养生物科学有限公司 Bifidobacteria for treating diabetes and related conditions
CN106619743A (en) * 2016-12-28 2017-05-10 山东龙力生物科技股份有限公司 Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink
CN109481510A (en) * 2018-10-11 2019-03-19 张军毅 It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof
CN111346114A (en) * 2018-12-21 2020-06-30 深圳市华大农业应用研究院 Application of lactobacillus reuteri
CN109998113A (en) * 2019-04-18 2019-07-12 广东省微生物研究所（广东省微生物分析检测中心） A kind of functional food of the probiotics preparation with effect of lowering blood sugar
CN111084385A (en) * 2019-04-18 2020-05-01 广东省微生物研究所（广东省微生物分析检测中心） Functional food of probiotic preparation with blood sugar reducing effect
CN110354148A (en) * 2019-08-19 2019-10-22 江南大学 Bifidobacterium adolescentis CCFM1061 is preparing the application in functional microbial inoculum, food and/or drug

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113197288A (en) * 2020-08-31 2021-08-03 内蒙古蒙牛乳业（集团）股份有限公司 Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof
CN113197288B (en) * 2020-08-31 2023-05-09 内蒙古蒙牛乳业（集团）股份有限公司 Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof
CN115137757A (en) * 2022-07-29 2022-10-04 承葛健康科技(广东)有限公司 Probiotic composition assisting in reducing blood sugar

Also Published As

Publication number Publication date
CN113197313B (en) 2023-10-27

Similar Documents

Publication Publication Date Title
CN110150669B (en) Probiotic composition suitable for diabetic patients and application thereof
US9737577B2 (en) Lactic acid bacterium-containing preparation
EP4140494A1 (en) Composition for preventing or treating lipid-related metabolic diseases, comprising lactobacillus plantarum atg-k2 or atg-k6
Carreras et al. Anti-obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zücker fatty rats
CN113197921B (en) Application of bifidobacterium lactis MN-Gup and microbial inoculum thereof in treating type 2 diabetes
EP3521415A1 (en) Novel lactobacillus sakei and composition comprising same
Liang et al. Probiotics improved hyperlipidemia in mice induced by a high cholesterol diet via downregulating FXR
CN113197313A (en) Probiotic composition with functions of improving insulin resistance and fasting blood glucose and preparation method thereof
JP2008174539A (en) Healthy and functional food for obesity patient using purple-colored potato
JP7267020B2 (en) Fermented milk with inhibitory effect on blood sugar level elevation
KR101545551B1 (en) The composition containing combination of 7 probiotics which have efficacy preventing from insulin resistance which cause type 2 diabetes mellitus as a effector component
CN112210518A (en) Lactobacillus reuteri and application thereof in reducing lipopolysaccharide concentration and improving insulin resistance
CN115381859A (en) Application of akkermansia muciniphila in preparation of pharmaceutical composition for preventing and treating diabetes, composition and application thereof
KR101282055B1 (en) Anti diabetic fermented food comprising fermented noni and method of manufacturing the same
CN113197288B (en) Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof
CN112708581A (en) Bifidobacterium adolescentis DH162 and fermentation product, application and microecological preparation thereof
JP2022506081A (en) Probiotic supplements for metabolic health containing Lactobacillus
CN111227240A (en) Meal replacement powder with blood sugar reducing effect and preparation method and application thereof
Wang et al. Glucose metabolic effects of oat noodles with different processing in type 2 diabetic mice
CN115466689A (en) Probiotic composition for preventing and/or treating metabolic diseases and application thereof
KR101504912B1 (en) The products containing probiotic lactobacillus acidophilus HY7037 having activity preventing from insulin resistance, which caused type 2 diabetes mellitus
TWI730719B (en) Plant fermented product, method of manufacturing the same, composition of plant fermented product and use thereof
JP2007054081A (en) Antiallergic food including ground lotus and/or lotus extract and lactic bacteria
CN115025132B (en) Synbiotic composition and preparation method and application thereof
KR101535077B1 (en) The products containing probiotic Bifidobacterium lactis HY8101 having activity preventing from insulin resistance, which caused type 2 diabetes mellitus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant